NCT02162836View on ClinicalTrials.gov

A Safety Study of JNJ-56021927 in Participants With Metastatic Castration-Resistant Prostate Cancer

PHASE1CompletedINTERVENTIONAL
Enrollment

6

Participants

Timeline

Start Date

June 27, 2014

Primary Completion Date

May 27, 2019

Study Completion Date

May 27, 2019

Conditions
Prostatic Neoplasms, Castration-Resistant
Interventions
DRUG

JNJ-56021927

Participants will receive 8 capsules of JNJ-56021927, 240 milligram (mg) as single oral dose on Day 1. After participants will receive daily JNJ-56021927, 240 mg on Day 1 of Cycle 1 until disease progression, unacceptable toxicity, withdrawal of consent or death, whichever comes first.

Trial Locations (4)

Unknown

Fukuoka

Gifu

Matsuyama

Yokohama

Sponsors
All Listed Sponsors
lead

Janssen Pharmaceutical K.K.

INDUSTRY

NCT02162836 - A Safety Study of JNJ-56021927 in Participants With Metastatic Castration-Resistant Prostate Cancer | Biotech Hunter | Biotech Hunter